DD128683A5 - Verfahren zur herstellung neuer polyhalogensteroide - Google Patents

Verfahren zur herstellung neuer polyhalogensteroide

Info

Publication number
DD128683A5
DD128683A5 DD7600196266A DD19626676A DD128683A5 DD 128683 A5 DD128683 A5 DD 128683A5 DD 7600196266 A DD7600196266 A DD 7600196266A DD 19626676 A DD19626676 A DD 19626676A DD 128683 A5 DD128683 A5 DD 128683A5
Authority
DD
German Democratic Republic
Prior art keywords
polyhalogen
steroids
producing new
producing
new
Prior art date
Application number
DD7600196266A
Other languages
German (de)
English (en)
Inventor
Jaroslav Kalvoda
Georg Anner
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25717430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DD128683(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CH1615175A external-priority patent/CH621801A5/de
Priority claimed from LU75903A external-priority patent/LU75903A1/xx
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of DD128683A5 publication Critical patent/DD128683A5/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DD7600196266A 1975-12-12 1976-12-10 Verfahren zur herstellung neuer polyhalogensteroide DD128683A5 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH1615175A CH621801A5 (en) 1975-12-12 1975-12-12 Process for the preparation of polyhalosteroids
LU75903A LU75903A1 (da) 1976-09-29 1976-09-29

Publications (1)

Publication Number Publication Date
DD128683A5 true DD128683A5 (de) 1977-12-07

Family

ID=25717430

Family Applications (1)

Application Number Title Priority Date Filing Date
DD7600196266A DD128683A5 (de) 1975-12-12 1976-12-10 Verfahren zur herstellung neuer polyhalogensteroide

Country Status (16)

Country Link
US (1) US4619921A (da)
JP (1) JPS5289662A (da)
AT (2) AT357703B (da)
AU (1) AU508224B2 (da)
CA (1) CA1056371A (da)
DD (1) DD128683A5 (da)
DE (1) DE2655570A1 (da)
DK (1) DK143708C (da)
ES (1) ES454120A1 (da)
FR (1) FR2334363A1 (da)
GB (1) GB1537130A (da)
HU (1) HU175583B (da)
IE (1) IE44473B1 (da)
IL (1) IL51087A (da)
NL (1) NL7613791A (da)
NZ (1) NZ182836A (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1209140B (it) * 1979-11-16 1989-07-10 Prochem Ets 6 alfa-fluoro-prednisolone 17,21-diesteri.
EP0078235A3 (de) * 1981-10-23 1983-06-29 Ciba-Geigy Ag Dihalogenierte Steroide
IT1319663B1 (it) * 2000-11-17 2003-10-23 Farmabios Srl Processo per la preparazione di fluoro-steroidi.
CA2473471A1 (en) * 2001-11-29 2003-06-12 Taro Pharmaceuticals U.S.A., Inc. Method for the preparation of 6-alpha-fluoro corticosteroids
US20040138192A1 (en) * 2003-01-13 2004-07-15 Chemagis Ltd. Crystalline forms of halobetasol propionate
US7208485B2 (en) * 2003-01-13 2007-04-24 Chemagis Ltd. Crystalline forms of halobetasol propionate
RU2387646C2 (ru) * 2003-08-29 2010-04-27 Рэнбакси Лабораториз Лимитед Ингибиторы фосфодиэстеразы типа-iv
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
US20070167420A1 (en) * 2005-04-07 2007-07-19 Daniella Gutman Process for preparing a crystalline form of halobetasol propionate
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
AU2006305620A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
WO2008035316A2 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
EA200900472A1 (ru) * 2006-09-22 2009-10-30 Ранбакси Лабораторис Лимитед Ингибиторы фосфодиэстеразы iv типа
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
SI2124944T1 (sl) * 2007-03-14 2012-05-31 Ranbaxy Lab Ltd Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US8962028B2 (en) 2012-10-18 2015-02-24 MiCal Pharmaceuticals LLC—H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limited Liability Company Topical steroid composition and method
HUE050603T2 (hu) 2015-06-18 2020-12-28 Bausch Health Ireland Ltd Egy kortikoszteroidot és egy retinoidot tartalmazó topikális készítmények psoriasis kezelésére
US11311482B2 (en) 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL241055A (da) * 1958-07-09
US3499016A (en) * 1958-08-04 1970-03-03 Upjohn Co 6alpha-fluoro-16alpha-methyl derivatives of the pregnane series
GB898292A (en) * 1959-03-18 1962-06-06 Upjohn Co Improvements in or relating to steroids and the manufacture thereof
CH513845A (de) * 1967-11-17 1971-10-15 Ciba Geigy Ag Verfahren zur Herstellung neuer Halogenpregnadiene
US3718673A (en) * 1971-02-01 1973-02-27 Du Pont Process for the preparation of 21-chloro-6,6,9alpha-trifluoro-11beta, alpha, 17alpha-trihydroxy-1,4-pregnadien-3,20-dione 16,17-ketals and selected intermediates
US4018918A (en) * 1975-05-20 1977-04-19 The Upjohn Company Topical clindamycin preparations
US3992422A (en) * 1975-08-14 1976-11-16 Schering Corporation Process for the preparation of 21-halogeno-21-desoxy-17α-acyloxy-20-keto-pregnenes

Also Published As

Publication number Publication date
DK557876A (da) 1977-06-13
FR2334363B1 (da) 1980-03-14
JPS5289662A (en) 1977-07-27
GB1537130A (en) 1978-12-29
DK143708C (da) 1982-03-15
AT357703B (de) 1980-07-25
HU175583B (hu) 1980-09-28
NZ182836A (en) 1979-01-11
IE44473B1 (en) 1981-12-16
DK143708B (da) 1981-09-28
CA1056371A (en) 1979-06-12
IL51087A0 (en) 1977-02-28
ATA913976A (de) 1979-12-15
NL7613791A (nl) 1977-06-14
IE44473L (en) 1977-06-12
ATA81279A (de) 1980-12-15
US4619921A (en) 1986-10-28
AT363201B (de) 1981-07-27
AU508224B2 (en) 1980-03-13
AU2047276A (en) 1978-06-15
ES454120A1 (es) 1978-02-16
FR2334363A1 (fr) 1977-07-08
DE2655570A1 (de) 1977-06-16
IL51087A (en) 1980-06-30

Similar Documents

Publication Publication Date Title
AT359217B (de) Verfahren zur herstellung neuer peptid-derivate
AT366361B (de) Verfahren zur herstellung neuer 2-aminotetraline
AT362363B (de) Verfahren zur herstellung neuer azetidinole
AT351510B (de) Verfahren zur herstellung neuer substituierter fluoracylresorcine
DD133949A5 (de) Verfahren zur herstellung neuer benzopyranderivate
AT352918B (de) Verfahren zur herstellung neuer histidin- derivate
AT358201B (de) Verfahren zur herstellung neuer kortikoide
ATA8777A (de) Verfahren zur herstellung von aminocyclolen
AT351046B (de) Verfahren zur herstellung neuer diharnstoffe
ATA736576A (de) Verfahren zur herstellung neuer indolderivate
AT360971B (de) Verfahren zur herstellung neuer alkinole
DD131169A5 (de) Verfahren zur herstellung neuer azatetracyclen
AT341531B (de) Verfahren zur herstellung neuer octahydropyridoindolobenzazepine
ATA797179A (de) Verfahren zur herstellung neuer kortikoide
ATA797079A (de) Verfahren zur herstellung neuer kortikoide
ATA759479A (de) Verfahren zur herstellung neuer ergolinderivate
ATA759579A (de) Verfahren zur herstellung neuer ergolinderivate
AT348162B (de) Verfahren zur herstellung neuer d-homosteroide
AT355239B (de) Verfahren zur herstellung neuer d-homosteroide
ATA590279A (de) Verfahren zur herstellung neuer 2-aminotetraline
ATA700078A (de) Verfahren zur herstellung neuer vincanol- und epivincanolderivate
ATA473079A (de) Verfahren zur herstellung neuer steroidketale
AT350528B (de) Verfahren zur herstellung neuer fluoracylresorcine
AT355027B (de) Verfahren zur herstellung neuer benzodiazepin- derivate
AT372386B (de) Verfahren zur herstellung neuer ergopeptidalkaloidderivate